Hepatitis C virus (HCV) is a single stranded positive RNA virus belonging to the Flaviviridae family. Although the mechanism of HCV replication is not fully understood, it is assumed that virus replication involves the synthesis of a negative strand RNA molecule that acts as a template for production of positive strand or genomic HCV-RNA. Thus detection of the HCV-RNA negative strand is indicative of viral replication. The liver is the main site of virus replication but it can also replicate at extrahepatic sites such as peripheral blood mononuclear cells (PBMC). Regarding this infection of PBMC, it has been shown that HCV can propagate in lymphoid cell cultures and that the virus derived from infection by detection of HCV-RNA positive and negative strands using a strand specific reverse transcriptase-polymerase chain reaction (RT-PCR) and by in situ hybridisation.

In a previous report, we described a group of patients with occult HCV infection and thus, although these patients do not have detectable serum HCV-RNA, they could be potentially infectious. HCV replicates in PBMC of patients with occult HCV infection and thus, although these patients do not have serum HCV-RNA, they could be potentially infectious. Occult hepatitis C virus (HCV) infection is characterised by the presence of HCV-RNA in the liver in the absence of anti-HCV, and serum viral RNA. Up to 70% of these patients also have HCV-RNA in peripheral blood mononuclear cells (PBMC) but it is not known if HCV is replicating in these cells.

Aim: We studied possible HCV replication in PBMC of 18 patients with an occult HCV infection who were selected on the basis of HCV-RNA positivity in PBMC.

Methods: Detection of HCV-RNA positive and negative strands in PBMC was done by strand specific reverse transcriptase-polymerase chain reaction (RT-PCR) and by in situ hybridisation.

Results: The presence of HCV-RNA positive strand in PBMC was confirmed in all patients by strand specific RT-PCR and by in situ hybridisation. Mean percentage of PBMC which had the HCV-RNA positive strand was 3.3% (95% confidence interval (CI) 2.1–4.4). The HCV-RNA negative strand was found in the PBMC of 11/18 (61%) patients by strand specific RT-PCR and confirmed by in situ hybridisation, and the percentage of PBMC harbouring the HCV-RNA negative strand was 3.1% (95% CI 0.8–5.5). There was a significant correlation (p = 0.001, r = 0.84) between the percentage of PBMC with the HCV-RNA positive strand and that of PBMC with the HCV-RNA negative strand.

Conclusion: HCV replicates in the PBMC of patients with occult HCV infection and thus, although these patients do not have serum HCV-RNA, they could be potentially infectious.

Patients and Methods
In a previous report, we described a group of patients with abnormal liver function tests of unknown aetiology who had occult HCV infection (HCV-RNA in the liver, as detected by RT-PCR and in situ hybridisation but anti-HCV and serum HCV-RNA negative). Among them, we selected for the present work those who: (i) were also HCV-RNA positive in the PBMC sample obtained on the same day of the liver biopsy and (ii) had available aliquots of that PBMC sample stored in liquid nitrogen. A total of 18 patients fulfilled the inclusion criteria and were included in this study, after giving written informed consent to participate. The characteristics of these 18 patients are shown in table 1. None reported risk factors (blood transfusions, drug abuse, sexual behaviour, tattoos, etc) for HCV infection. Four of these 18 patients had abnormal levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyl transferase (GGTP) simultaneously; five had abnormal values of two liver enzymes (ALT and GGTP four patients; ALT and AST one patient), and the remaining nine patients had abnormal levels of only one liver enzyme (GGTP six patients and ALT three patients). PBMC samples from six healthy volunteers with normal liver function tests, who were repeatedly HCV-RNA negative in PBMC, were used as negative controls.

Total RNA was isolated from PBMC using the SV Total RNA Isolation System (Promega Corp., Madison, Wisconsin, USA) and, after precipitation, the RNA pellet was dissolved in diethyl-pyrocarbonate treated water. The amount of total RNA was determined by spectrophotometry and 0.5 μg of RNA were used for detection of HCV-RNA of both polarities.

Synthetic HCV-RNA
Synthetic HCV-RNA positive and negative strands were generated by in vitro transcription of the recombinant plasmid pc5NCR, which contains the complete 5’ non-coding region of the HCV genome. After plasmid linearisation, the RNA positive and negative strands were synthesised.

Abbreviations: FISH, fluorescent in situ hybridisation; HCV, hepatitis C virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGTP, gamma-glutamyl transferase; PBMC, peripheral blood mononuclear cells; RT-PCR, reverse transcriptase-polymerase chain reaction.
PCR contamination. agarose gel electrophoresis.

The HCV-RNA positive strand was detected using a cRNA probe spanning 390 nucleotides of the HCV core coding region, obtained by in vitro transcription of the pCore plasmid.

For fluorescent in situ hybridisation (FISH), PBMC were resuspended in KCl (0.075 M) for 10 minutes at 37°C, pelleted at 500 g for five minutes, and resuspended in 15 µl of phosphate buffered saline. Resuspended cells were mixed with 35 µl of low melting point agarose maintained at 37°C, deposited onto a glass slide (that was previously precoated with 0.65% standard agarose and dried at 80°C), covered with a cover slip, and allowed to solidify at 4°C. Finally, coverslips were gently removed by immersing the slides in phosphate buffered saline at room temperature. Hybridisation with both HCV-RNA riboprobes was carried out at 42°C for 16 hours in a humid chamber. After hybridisation, samples were washed at 42°C in 2×SSC, 0.5×SSC, and 0.1×SSC (15 minutes each) (20×SSC: 3 M NaCl, 3 mM trisodium citrate). Digoxigenin labelled hybrids were detected with fluorescein isothiocyanate conjugate (Roche Molecular Biochemicals). Signal intensity was amplified using the Fluorescent Antibody Enhancer set for DIG detection kit (Roche Molecular Biochemicals). Cells were counterstained with 4-6 diamidino-2-phenylindole. Fluorescent signals were observed using a Nikon Eclipse E-400 light-microscope (Nikon Co., Tokyo, Japan) and the images were captured with a high resolution monochrome CCD camera (DIC-N; Wared Precision Instruments, Cambridge, UK) At least 2000 cells per sample were counted to obtain the percentage of positive cells.

Strand specific RT-PCR

Specific detection of HCV-RNA positive and negative strands was done by performing the corresponding DNA synthesis at high temperature using the thermostable enzyme Tth. Briefly, cDNA synthesis was carried out in 20 µl of reaction buffer consisting of 50 mM of the corresponding primer from the 5’ NC region of the HCV genome, 1 x RT buffer (Applied Biosystems, Foster City, California, USA), 1 mM MnCl₂, 200 µM of each deoxynucleoside triphosphate, and 5 U of rTth (Applied Biosystems). After 20 minutes at 65°C, Mn²⁺ was chelated with 8 µl of the 10× chelating buffer (Applied Biosystems). Thereafter, 50 µM of the opposite primer was added, the volume adjusted to 100 µl, and the MgCl₂ concentration adjusted to 2.2 mM. Amplification was performed as follows: initial denaturing for two minutes at 94°C and 30 cycles of 94°C for 30 seconds, 55°C for 30 seconds, and 72°C for one minute followed by a final extension at 72°C for seven minutes. For detection of the HCV-RNA positive strand, the cDNA reverse primer was 5’CAT GGT GCA CCG TCT ACG AGA CC 3’ and the forward primer was 5’GGC GAC ACT CCA CCA TGA ATC AC 3’. The same primers were used in reverse order for detection of the HCV-RNA negative strand.

A sample of the RT-PCR reaction (10 µl) was added to the second nested PCR and amplified for another 30 cycles, using as inner forward primer, 5’CTG TGA GGA ACT ACT GTC TT 3’, and as the reverse inner primer, 5’CTC GCA AGC ACC CTA TCA GG 3’. PCR products (266 bp) were visualised by 1.4% agarose gel electrophoresis.

During extraction, RT, and amplification steps, the guidelines of Kvak and Hijugu were carefully followed to prevent PCR contamination.12

Detection of HCV-RNA positive and negative strands in PBMC by fluorescent in situ hybridisation

The HCV-RNA positive strand was detected using a cRNA probe of negative polarity obtained by in vitro transcription of the pC5’NCR in the presence of digoxigenin-11-UTP (Roche Molecular Biochemicals, Indianapolis, Indiana, USA).

by transcription from the SP6 RNA polymerase promoter or the T7 RNA polymerase promoter, respectively. The plasmid template was removed by two rounds of digestion for 30 minutes at 37°C with 1 µg DNA of DNase I (Promega), followed by phenol-chloroform extraction. Concentrations of both HCV-RNA strand transcripts were determined spectrophotometrically and the absence of residual DNA was assayed by PCR without the RT step. Tenfold serial dilutions of the RNA templates were made in RNA extracted from a HCV negative cell line (HepeG2) such that all dilutions had a final concentration of 0.5 µg of total RNA.

Table 1. Characteristics of the patients with occult hepatitis C virus (HCV) infection included in the study

<table>
<thead>
<tr>
<th>No. of patients</th>
<th>18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (M/F)</td>
<td>13/5</td>
</tr>
<tr>
<td>Age (years)</td>
<td>45.7 (41.0–50.3)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>25.3 (24.2–26.5)</td>
</tr>
<tr>
<td>Estimated duration of abnormal liver function tests (months)</td>
<td>35.5 (14.3–56.7)</td>
</tr>
</tbody>
</table>

Values are mean (95% confidence interval of the mean) or number.

Strand specific RT-PCR

Specific detection of HCV-RNA positive and negative strands was done by performing the corresponding DNA synthesis at high temperature using the thermostable enzyme Tth. Briefly, cDNA synthesis was carried out in 20 µl of reaction buffer consisting of 50 mM of the corresponding primer from the 5’ NC region of the HCV genome, 1 x RT buffer (Applied Biosystems, Foster City, California, USA), 1 mM MnCl₂, 200 µM of each deoxynucleoside triphosphate, and 5 U of rTth (Applied Biosystems). After 20 minutes at 65°C, Mn²⁺ was chelated with 8 µl of the 10× chelating buffer (Applied Biosystems). Thereafter, 50 µM of the opposite primer was added, the volume adjusted to 100 µl, and the MgCl₂ concentration adjusted to 2.2 mM. Amplification was performed as follows: initial denaturing for two minutes at 94°C and 30 cycles of 94°C for 30 seconds, 55°C for 30 seconds, and 72°C for one minute followed by a final extension at 72°C for seven minutes. For detection of the HCV-RNA positive strand, the cDNA reverse primer was 5’CAT GGT GCA CCG TCT ACG AGA CC 3’ and the forward primer was 5’GGC GAC ACT CCA CCA TGA ATC AC 3’. The same primers were used in reverse order for detection of the HCV-RNA negative strand.

A sample of the RT-PCR reaction (10 µl) was added to the second nested PCR and amplified for another 30 cycles, using as inner forward primer, 5’CTG TGA GGA ACT ACT GTC TT 3’, and as the reverse inner primer, 5’CTC GCA AGC ACC CTA TCA GG 3’. PCR products (266 bp) were visualised by 1.4% agarose gel electrophoresis.

During extraction, RT, and amplification steps, the guidelines of Kvak and Hijugu were carefully followed to prevent PCR contamination.12

Detection of HCV-RNA positive and negative strands in PBMC by fluorescent in situ hybridisation

The HCV-RNA positive strand was detected using a cRNA probe of negative polarity obtained by in vitro transcription of the pC5’NCR in the presence of digoxigenin-11-UTP (Roche Molecular Biochemicals, Indianapolis, Indiana, USA).

Detection of the HCV-RNA negative strand was performed with a complementary digoxigenin labelled cRNA probe spanning 390 nucleotides of the HCV core coding region, obtained by in vitro transcription of the pCore plasmid.

For fluorescent in situ hybridisation (FISH), PBMC were resuspended in KCl (0.075 M) for 10 minutes at 37°C, pelleted at 500 g for five minutes, and resuspended in 15 µl of phosphate buffered saline. Resuspended cells were mixed with 35 µl of low melting point agarose maintained at 37°C, deposited onto a glass slide (that was previously precoated with 0.65% standard agarose and dried at 80°C), covered with a cover slip, and allowed to solidify at 4°C. Finally, coverslips were gently removed by immersing the slides in phosphate buffered saline at room temperature. Hybridisation with both HCV-RNA riboprobes was carried out at 42°C for 16 hours in a humid chamber. After hybridisation, samples were washed at 42°C in 2×SSC, 0.5×SSC, and 0.1×SSC (15 minutes each) (20×SSC: 3 M NaCl, 3 mM trisodium citrate). Digoxigenin labelled hybrids were detected with fluorescein isothiocyanate conjugate (Roche Molecular Biochemicals). Signal intensity was amplified using the Fluorescent Antibody Enhancer set for DIG detection kit (Roche Molecular Biochemicals). Cells were counterstained with 4-6 diamidino-2-phenylindole. Fluorescent signals were observed using a Nikon Eclipse E-400 light-microscope (Nikon Co., Tokyo, Japan) and the images were captured with a high resolution monochrome CCD camera (DIC-N; Wared Precision Instruments, Cambridge, UK) At least 2000 cells per sample were counted to obtain the percentage of positive cells.

Statistical analysis

Data analysis was performed using SSPS version 9.0 for windows (Chicago, Illinois, USA). Normality and homoscedasticity of continuous variables were tested by the Komolgorov-Smirnov and Levene’s tests, respectively. The mean was compared with the Student’s t (variables with normal distribution) or with the Mann-Whitney U test (variables with non-normal distribution). Categorical variables were compared using the χ² or Fisher’s exact tests. Pearson (variables with Gaussian distribution) or Spearman (non-normally distributed variables) correlation coefficients were determined to study the existence of correlation between the variables. All tests performed were two sided and statistical significance was considered at a p value <0.05.

RESULTS

To assess the sensitivity and specificity of our strand specific RT-PCR assay, serial dilutions of synthetic HCV-RNA positive and negative strands were used as RNA templates. The analysis showed that the positive strand assay detected the HCV-RNA positive strand at 0.1 fg and the HCV-RNA negative strand at 10 pg (fig 1A). Thus, discrimination was 100 000-fold. Similarly, the negative strand assay detected the HCV-RNA negative strand at 1 fg while the RNA positive strand was detected at 10 pg (fig 1B), resulting in a 10 000-fold discrimination.

The results obtained by strand specific RT-PCR assay as well as by the FISH technique confirmed that all 18 patients with occult HCV infection had the HCV-RNA positive strand in their PBMC. In contrast, PBMC from six healthy donors were negative. Mean percentage of PBMC showing fluorescent signals for the HCV-RNA positive strand was 3.3% (95% confidence interval (CI) 2.1–4.4).

When studying the presence of the RNA negative strand in PBMC, we found that 11/18 (61%) patients were positive by the strand specific RT-PCR. The existence of the HCV-RNA negative strand was confirmed by FISH in these 11 cases while no hybridisation signals were seen in the PBMC of the
remaining seven patients. PBMC samples from the healthy donors were negative for the RNA negative strand by both techniques. In 11 patients with occult HCV infection, mean percentage of PBMC with a positive hybridisation signal for the HCV-RNA negative strand was 3.1% (95% CI 0.8–5.5).

When patients were divided according to the status of HCV replication in their PBMC, we found that the mean percentage of PBMC cells harbouring the HCV-RNA positive strand was significantly higher ($p = 0.009$) in those patients with HCV replication in PBMC (mean 4.2% (95% CI 2.5–5.9)) than in those without HCV replication (mean 1.8% (95% CI 1.3–2.2)). No other differences were found between the groups of patients (table 2).

In contrast, there was a significant correlation ($p = 0.001$, $r = 0.84$) between the percentage of PBMC with the HCV-RNA positive strand and that of PBMC with the HCV-RNA negative strand was significantly higher ($p = 0.009$) in those patients with HCV replication in PBMC (mean 4.2% (95% CI 2.5–5.9)) than in those without HCV replication (mean 1.8% (95% CI 1.3–2.2)). No other differences were found between the groups of patients (table 2).

### Table 2

<table>
<thead>
<tr>
<th>HCV replication in PBMC</th>
<th>Positive</th>
<th>Negative</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No of patients</td>
<td>11</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>8/3</td>
<td>5/2</td>
<td>1.0</td>
</tr>
<tr>
<td>Age (y)</td>
<td>46.5 (40.1–52.8)</td>
<td>44.4 (35.4–53.5)</td>
<td>0.668</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>26.0 (24.2–27.7)</td>
<td>24.3 (24.3–25.3)</td>
<td>0.083</td>
</tr>
<tr>
<td>Estimated duration of abnormal liver function tests (months)</td>
<td>41.4 (6.9–75.8)</td>
<td>26.3 (3.5–49.0)</td>
<td>0.236</td>
</tr>
<tr>
<td>AST (IU/l)</td>
<td>43.7 (21.4–66.0)</td>
<td>25.7 (18.6–32.8)</td>
<td>0.069</td>
</tr>
<tr>
<td>ALT (IU/l)</td>
<td>61.3 (22.8–99.8)</td>
<td>43.1 (20.3–66.0)</td>
<td>0.375</td>
</tr>
<tr>
<td>GGTP (IU/l)</td>
<td>147.4 (69.6–225.2)</td>
<td>68.0 (39.5–96.5)</td>
<td>0.052</td>
</tr>
<tr>
<td>Liver</td>
<td>3.6 (1.0–6.2)</td>
<td>3.9 (0.9–7.0)</td>
<td>0.851</td>
</tr>
<tr>
<td>HCV-RNA positive strand (%)</td>
<td>3.0 (0.3–4.0)</td>
<td>2.3 (1.4–3.3)</td>
<td>0.866</td>
</tr>
<tr>
<td>PBMC</td>
<td>4.2 (2.5–5.9)</td>
<td>1.8 (1.3–2.2)</td>
<td>0.009</td>
</tr>
</tbody>
</table>

Values are mean (95% confidence interval of the mean) or number.
BMI, body mass index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGTP, gamma-glutamyl transpeptidase.
negative strand (fig 2). However, no correlations were seen between the percentages of HCV-RNA positive or negative strands in PBMC and in hepatocytes. In addition, the existence of HCV replication in PBMC was not related to the presence of HCV replication in the liver (data not shown).

**DISCUSSION**

In the present work, we investigated if HCV replicates in the PBMC of 18 patients with occult HCV infection (who had HCV-RNA in their PBMC) by specific detection of viral RNA positive and negative strands using two techniques: a highly specific RT-PCR assay and FISH. The specificity of our RT-PCR assay was assessed with serial dilutions of synthetic HCV-RNA positive and negative strands, showing 10 000–100 000-fold differentials between detection of the correct and incorrect strands of RNA. These differentials confirm the specificity of HCV-RNA negative strand detection in PBMC as in vivo the HCV-RNA positive-negative strand ratio is 10–100-fold.

Detection of the HCV-RNA positive strand by RT-PCR and FISH confirmed the existence of HCV infection in the PBMC of the 18 patients with occult HCV infection included in the study. Analysis of the HCV-RNA negative strand showed that HCV was replicating in the PBMC of the majority (61%) of patients with occult HCV infection, with concordant results between the two different techniques. This percentage of HCV infection in PBMC of patients with occult HCV infection is similar to that reported in PBMC of patients with chronic hepatitis C.

The existence of HCV infection and replication in PBMC in the absence of detectable serum HCV-RNA has also been described in anti-HCV positive patients years after spontaneous or antiviral therapy induced clearance of serum viral RNA and normalisation of transaminases. As there is no detectable circulating viral RNA, it could be assumed that HCV infection and replication in PBMC may be related to the status of intrahepatic HCV-RNA. However, in these patients with occult HCV infection, we did not find any correlation between the percentage of hepatocytes showing the HCV-RNA positive or negative strand and these percentages in PBMC. Moreover, the existence of HCV replication in PBMC was not related to the presence of HCV replication in the liver. Whether this lack of association reflects infection with HCV variants of different tropisms or with different replication capacities is currently under investigation.

In contrast, the percentage of PBMC harbouring the HCV-RNA positive and negative strands were highly correlated with each other (r = 0.84; p = 0.001) and the mean percentage of infected PBMC was significantly higher (p = 0.009) in patients with HCV replication in PBMC than in those without HCV replication. Taking into account that if replication occurs the HCV-RNA positive-negative ratio is within 10–100-fold, perhaps in these negative cases HCV replication is taking place but at such a low level that detection is beyond the sensitivity of the assay.

In conclusion, our findings indicate that HCV replicates in the PBMC of patients with occult HCV infection. As it has been shown that HCV can propagate in lymphoid cell cultures and that the virus derived is infectious, it should be determined whether these patients (although they do not have detectable circulating viruses) are potentially infectious.

**ACKNOWLEDGEMENTS**

This work was partially supported by a grant from the Fundación Accenture, Madrid, Spain.

**Authors' affiliations**
I Castillo, E Rodriguez-Iriigo, J Bartolome, S de Lucas, N Ortiz-Movilla, J M Lopez-Alaraco, M Pardo, V Carreño, Fundación para el Estudio de las Hepatitis Virales, Madrid, Spain

Conflict of interest: None declared.

**REFERENCES**
1. Miller RH, Purcell RH. Hepatitis C virus shares amine acid sequence similarity with pestiviruses and flaviviruses, as well as members of two plant virus supergroups. Proc Natl Acad Sci U S A 1990;87:2057–61.
Hepatitis C virus replicates in peripheral blood mononuclear cells of patients with occult hepatitis C virus infection

I Castillo, E Rodríguez-Iñigo, J Bartolomé, S de Lucas, N Ortíz-Movilla, J M López-Alcorocho, M Pardo and V Carreño

Gut 2005 54: 682-685
doi: 10.1136/gut.2004.057281

Updated information and services can be found at:
http://gut.bmj.com/content/54/5/682

These include:

References
This article cites 14 articles, 7 of which you can access for free at:
http://gut.bmj.com/content/54/5/682#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/